Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Payables (2016 - 2025)

Karyopharm Therapeutics' Payables history spans 14 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Payables fell 21.62% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 21.62%, while the annual FY2025 figure was $4.0 million, 21.62% down from the prior year.
  • Payables reached $4.0 million in Q4 2025 per KPTI's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.0 million in Q1 2023 to a low of $813000.0 in Q3 2022.
  • Average Payables over 5 years is $3.4 million, with a median of $2.9 million recorded in 2021.
  • Peak YoY movement for Payables: tumbled 63.98% in 2021, then soared 513.26% in 2024.
  • A 5-year view of Payables shows it stood at $1.6 million in 2021, then surged by 72.99% to $2.8 million in 2022, then rose by 12.62% to $3.1 million in 2023, then surged by 63.53% to $5.1 million in 2024, then fell by 21.62% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Payables are $4.0 million (Q4 2025), $5.4 million (Q3 2025), and $2.6 million (Q2 2025).